The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation

Bibliography

• BECK 0, WALLEN NK, BROIJERSEN A, LARSSON PT, HJEMDAHL P: On the accurate determination of serotonin in human plasma. Biochem. Biophys. Res. Comm. (1993) 196:260–266.
   PubMed Web of Science ®Google Scholar
• HOYER D, HANNON JP, MARTIN GR: Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. (2002) 71:533–554.
   PubMed Web of Science ®Google Scholar
• •Good review of 5-HT receptors and function.
   Google Scholar
• NEBIGIL CG, CHOI DS, DIERICH A et al.: Serotonin 2B receptor is required for heart development. Proc. Natl. Acad. Sci. USA (2000) 97:9508–9513.
   PubMed Web of Science ®Google Scholar
• •Demonstrated that 5-HT2B is necessary for heart development.
   Google Scholar
• NEBIGIL CG, MAROTEAUX L: A novel role for serotonin in heart. Trends Cardiovasc. Med. (2001) 11:329–335.
   PubMed Web of Science ®Google Scholar
• KAUMANN AJ, SANDERS L, BROWN AM, MURRAY KJ, BROWN MJ: A 5-hydroxytryptamine receptor in human atrium. Br. J. Pharmacol. (1990) 100:879–885.
   PubMed Web of Science ®Google Scholar
• SANDERS L, LYNHAM JA, BOND B et al.: Sensitization of human atrial 5-HT4 receptors by chronic beta-blocker treatment. Circulation (1995) 92:2526–2539.
   PubMed Web of Science ®Google Scholar
• KAUMANN AJ: Do human atrial 5-HT 4 receptors mediate arrhythmias? Trends Pharrmacol. Sci. (1994) 15:451–455.
   Google Scholar
• OUADID H, DEGUIN J, DUMUIS A, BOCKAERT J, NARGEOT J: Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine4 receptors. Mol. Pharmacol. (1992) 41:346–351.
   PubMed Web of Science ®Google Scholar
• PINO R, CERBAI E, CALAMAI G et al: Effect of 5-HT4receptor stimulation on the pacemaker current If in human isolated atrial myocytes. Cardiovasc. Res. (1998) 40:516–522.
   PubMed Web of Science ®Google Scholar
• EFTEKHARI P, SALLE. L, LEZOUALC'H F et al: Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eui: Immunol. (2000) 30:2782–2790.
   PubMed Web of Science ®Google Scholar
• BUYON JP, CLANCY R, DI DONATO F et al.: Cardiac 5-HT4serotoninergic receptors, 52kD SSA/Ro and autoimmune-associated congenital heart block. Autoimmun. (2002) 19:79–86.
   Google Scholar
• JICK H, VASILAKIS C, WEINRAUCH LA et al.: A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl. ". Med. (1998) 339:719–724.
   Google Scholar
• •Links appetite suppressants to valvular heart disease.
   Google Scholar
• CONNOLLY HM, CRARY JL, MCGOON MD et al.: Valvular heart disease associated with fenfluramine-phentermine. N Engl. J. Med. (1997) 337:581–588.
   PubMed Web of Science ®Google Scholar
• •Links appetite suppressants to valvular heart disease.
   Google Scholar
• KULKE MH, MAYER RI: Carcinoid tumors. N Engl. J. Med. (1999) 340:858–868.
   PubMed Web of Science ®Google Scholar
• FITZGERALD LW, BURN TC, BROWN BS et al.: Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. (2000) 57:75–81.
   PubMed Web of Science ®Google Scholar
• ROTHMAN RB, BAUMANN MH, SAVAGE JE et al.: Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation (2000) 102:2836–2841.
   PubMed Web of Science ®Google Scholar
• HAFIZI S, TAYLOR PM, CHESTER AH, ALLEN SP, YACOUB MH: Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents. J. Heart Valve Dis. (2000) 9:454–458.
   PubMed Web of Science ®Google Scholar
• CHESTER AH, MISFELD M, SIEVERS HH, YACOUB MH: Influence of 5-hydroxytryptamine on aortic competence M vitro. J. Heart Valve Dis. (2001) 10:822–825.
   PubMed Web of Science ®Google Scholar
• NILSSON T, LONGMORE J, SHAW D et al.: Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Ear: Pharmacol (1999) 372:49–56.
   PubMed Web of Science ®Google Scholar
• AUCH-SCHWELK W, PAETSCH I, KRACKHARDT E et al.: Modulation of contractions to ergonovine and methylergonovine by nitric oxide and thromboxane A2 in the human coronary artery. J. Cardiovasc. Pharmacol (2000) 36:631–639.
   PubMed Web of Science ®Google Scholar
• MCFADDEN EP, CLARKE JG, DAVIES GJ et al.: Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N. Engl. J. Med. (1991) 324:648–654.
   PubMed Web of Science ®Google Scholar
• GOLINO P, PISCIONE F, WILLERSON JT et al.: Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl. J. Med. (1991) 324:641–648.
   PubMed Web of Science ®Google Scholar
• ISCHIDA I, KAWASHIMA S, HIRATA K-I et al.: Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation (2001) 103:1289–1295.
   PubMed Web of Science ®Google Scholar
• MA L, YU Z, XIAO S et al: Supersensitivity to serotonin- and histamine-induced arterial contraction following ovariectomy. Ear: Pharmacol (1998) 359:191–200.
   PubMed Web of Science ®Google Scholar
• ZWAVELING J, PFAFFENDORF M, VAN ZWIETEN PA: The influence of hyperthyroidism on vasoconstrictor and vasodilator responses in silated coronary and renal resistance arteries. Pharmacology (1997) 55:117–125.
   PubMed Web of Science ®Google Scholar
• METAIS C, BIANCHI C, LI J et al: Serotonin-induced human coronary microvascular contraction during acute myocardial ischemia is blocked by COX-2 inhibition. Basic Res. Cardiol (2001) 96:59–67.
   PubMed Web of Science ®Google Scholar
• VIKENES K, FARSTAD M, NORDREHAUG JE: Serotonin is associated with coronary artery disease and cardiac events. Circulation (1999) 100:483–489.
   PubMed Web of Science ®Google Scholar
• VAN DEN BERG EK, SCHMITZ JM, BENEDICT CR et al: Transcardiac serotonin concentration is increased in selective patients with limiting angina and complex coronary lesion morphology. Circulation (1989) 79:116–124.
   PubMed Web of Science ®Google Scholar
• GOLINO P, PISCIONE F, BENEDICT CR et al.: Local effect of serotonin released during coronary angioplasty. N Engl. J. Med. (1994) 330:523–528.
   PubMed Web of Science ®Google Scholar
• LEOSCO D, FINES CHI M, PIERLI C et al.: Intracoronary serotonin release after high-pressure coronary stenting. Am. J. Cardiol (1999) 84:1317–1322.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, KLEIN W, TIJSSEN JP et al.: Evaluation of ketanserin in the prevention of restenosis after percutaneoous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. Circulation (1993) 88:1588–1601.
   Google Scholar
• •Clinical trial showing ketanserin is ineffective in restenosis.
   Google Scholar
• LONGMORE J, BOULANGER CM, DESTRA Bet al.: 5-HT1D receptor agonists and human coronary artery reactivity in vitro crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br: J. Clin. Pharmacol (1996) 42:431–441.
   Google Scholar
• FU L-W, LONGHURST JC: Activated platelets contribute to stimulation of cardiac afferents during ischaemia in cats: role of 5-HT3 receptors. J. Physic] (2002) 544:897–912.
   Google Scholar
• MURAKAMI Y, ISHINAGA Y, SANO K et al.: Increased serotonin release across the coronary bed during a nonischemic interval in patients with vasospastic angina. Clin. Cardiol (1996) 19:473–476.
   PubMed Web of Science ®Google Scholar
• ISHIDA T, HIRATA K, SAKODA T et al.:5-HT1Dbeta receptor mediated the supersensitivity of isolated coronary artery to serotonin in variant angina. Chest (1998) 113:243–244.
   PubMed Web of Science ®Google Scholar
• MIYATA K, SHIMOKAWA H, HIGO T et al.: Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. J. Cardiovasc. Pharmacol (2000) 35:294–301.
   PubMed Web of Science ®Google Scholar
• YAMADA S, AKITA H, KANAZAWA K et al.: T102C polymorphism of the serotonin (5-HT)2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis (2000) 150:143–148.
   PubMed Web of Science ®Google Scholar
• GROVER GJ, SARGENT CA, DZWONCZYK S, NORMANDIN DE, ANTONACCIO MJ: Protective effect of serotonin (5-HT2) receptor antagonists in ischemic rat hearts. Cardiovasc. Pharmacol (1993) 22:664–672.
   PubMed Web of Science ®Google Scholar
• GROVER GJ, PARHAM CS, YOUSSEF S,OGLETREE ML: Protective effect of the serotonin receptor antagonist cinanserin in two canine models of pacing-induced myocardial ischemia. Pharmacology (1995) 50:286–297.
   PubMed Web of Science ®Google Scholar
• HOODS, BIRNIE D, NASSER A, HILLIS WS: Effect of ketanserin on central haemodynamics and coronary circulation. Cardiovasc. Pharmacol (1998) 32:983–987.
   PubMed Web of Science ®Google Scholar
• ISRAILOVA M, SUZUKI F, TANAKA T et al.: Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes. Pharmacology (2002) 65:69–73.
   PubMed Web of Science ®Google Scholar
• SHIMIZU T, MINATOGUCHI S, HASHIMOTO K et al: The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hears.' Am. Coll. Cardiol (2002) 40:1347–1355.
   PubMed Web of Science ®Google Scholar
• WRIGHT L, HOMANS DC, LAXSON DD, DAI YZ, BACHE RJ: Effect of serotonin and thromboxane A2 on blood flow through moderately well developed coronary collateral vessels." Am. Coll. Cardiol (1992) 19:687–693.
   PubMed Web of Science ®Google Scholar
• TANAKA T, FUJITA M, NAKAE I et al.:Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. I Am. Coll. Cardiol (1998) 32:1982–1986.
   PubMed Web of Science ®Google Scholar
• KINUGAWA T, FUJITA M, LEE JD et al:Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with anginal pectoris. Am. Heart J. (2002) 144:E2.
   PubMedGoogle Scholar
• SATOMURA K, TAKASE B, HAMABE A et al.: Sarpogrelate, a specific 5-HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease. Clin. Cardiol. (2002) 25:28–32.
   PubMed Web of Science ®Google Scholar
• TEMSAH RM, KUMAMOTO H, TAKEDA N, DHALLA NS: Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart. Can. J. Physiol. Pharmacol. (2001) 79:761–767.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, DEL RIZZO DEX, ZAHRADKA P et al.: Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. Ann. Thome. Surg. (2001) 71:1856–1865.
   PubMed Web of Science ®Google Scholar
• IKEDA K, TOJO K, TOKUDOME G et al: The effects of sarpogrelate on cardiomyocyte hypertrophy. Life Sci. (2000) 67:2991–2996.
   PubMed Web of Science ®Google Scholar
• BERRY CN, LORRAIN J, LOCHOT S et al: Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1g/ 5-HT 2A receptor antagonist. Thromb. Haemost. (2001) 85:521–528.
   Google Scholar
• MACLEAN MR, HERVE P, EDDAHIBI S, ADNOT S: 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br. .1. Pharmacol. (2000) 131:161–168.
   Google Scholar
• •Concise review linking 5-HT to PH.
   Google Scholar
• ULLMER C, SCHMUCK K, KALKMAN HO, LUBBERT H: Expression of serotonin receptor mRNA in blood vessels. FEBS Lett. (1995) 370:215–221.
   PubMed Web of Science ®Google Scholar
• NOVIK-GRAYCK E, MCMAHON TJ, HUANG YC et al.: Pulmonary vasoconstriction is inhibited by nitroglutathione. Am. J. Physiol. Lung Cell Mol. Physiol. (2002) 282:11057–11065.
   Google Scholar
• SITCOM 0, HUMBERT M, SIMONNEAU G: Primary pulmonary hypertension: current therapy. Frog. Cardiovasc. Dis. (2002) 45:115–128.
   PubMedGoogle Scholar
• LAM CE SVIRI S, ILETT KF, VAN HEERDEN PV: Inhaled diazeniumdiolates (NONOates) as selective pulmonary vasodilators. Expert Opin. Investig. Drugs (2002) 11(7):897–909.
   PubMed Web of Science ®Google Scholar
• MACLEAN MR, CLAYTON RA, TEMPLETON AG, MORE CROFT I: Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br. J. Pharmacol. (1996) 119:277–282.
   PubMed Web of Science ®Google Scholar
• MORE CROFT I, HEELEY RP, PRENTICE HM, KIRK A, MACLEAN MR: 5-hydroxytrytamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br. J Pharmacol. (1999) 126:730–734.
   PubMedGoogle Scholar
• MACINTYRE PD, BHARGAVA B, HOGG KJ, GEMMILL JD, HILLIS WS: The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br. J Clin. Pharmacol. (1992) 34:541–546.
   Google Scholar
• GLUSA E, PERTZ HH: Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT2B receptors. Br. J Pharmacol. (2000) 130:692–698.
   PubMed Web of Science ®Google Scholar
• MACLEAN MR, CLAYTON RA, HILLIS SW et al.: 5-HT1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone. Palm. Pharmacol. (1994) 7:65–72.
   Google Scholar
• LEE SL, WANG WW, LANZILLO JJ, FANBURG BL: Serotonin produced both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am. J. Physiol. (1994) 266:L46–L52.
   PubMed Web of Science ®Google Scholar
• LEE SL, WANG WW, MOORE BJ, FANBURG BL: Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ. Res. (1991) 68:1362–1368.
   PubMed Web of Science ®Google Scholar
• HERVE P, LAUNAY J-M, SCROBOHACI M-L et al.: Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. (1995) 99:249–254.
   PubMed Web of Science ®Google Scholar
• KERVEUR A, CALLEBERT J, HUMBERT M et al.: High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler. Thrornb. Vase. Biol. (2000) 20:2233–2239.
   PubMed Web of Science ®Google Scholar
• EGERMAYER P, TOWN GI, PEACOCK AJ: Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax (1999) 54:161–168.
   PubMed Web of Science ®Google Scholar
• MACLEAN MR, SWEENEY G, BAIRD M et al.: 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br. .1. Pharmacol. (1996) 119:917–930.
   Google Scholar
• EDDAHIBI S, RAFFESTIN B, PHAM I et al.: Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am. J Physiol. (1997) 272:H1173–H1181.
   PubMed Web of Science ®Google Scholar
• ABENHAIM L, MORIDE Y, BRENOT F et al.: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. New Eng] J. Med. (1996) 335:609–615.
   PubMed Web of Science ®Google Scholar
• •Links appetite suppressants to PH.
   Google Scholar
• HIGENBOTTAM T, MARRIOT H, CREMONA G, LAUDE E, BEE D: The acute effects of dexfenfluramine in human and porcine pulmonary vascular tone and resistance. Chest (1999) 116:921–930.
   PubMed Web of Science ®Google Scholar
• MITANI Y, MUTLU A, RUSSELL JC et al.: Dexfenfluramine protects against pulmonary hypertension in rats. J. Appl. Physiol. (2002) 93:1770–1778.
   PubMed Web of Science ®Google Scholar
• ROTHMAN RB, AYESTAS MA, DERSCH CM, BAUMANN MH: Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation (1999) 100:869–875.
   PubMed Web of Science ®Google Scholar
• EDDAHIBI S, ADNOT S, FRISDAL E et al.: Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J Pharmacol. Exp. Ther. (2001) 297:148–154.
   PubMed Web of Science ®Google Scholar
• WEIR EK, REEVE HL, HUANG JMC et al.: Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary in rat smooth muscle and cause pulmonary vasoconstriction. Circulation (1996) 94:2216–2220.
   PubMed Web of Science ®Google Scholar
• LEE S-L, WANG W-W, FANBURG BL: Dexfenfluramine as a mitogen signals through the formation of superoxide anion. FASEB J (2001) 15(7):1324–1325.
   PubMed Web of Science ®Google Scholar
• EDDAHIBI S, PABRE V, BONI C et al:Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with mitogenic action of serotonin. Circ. Res. (1999) 84:329–336.
   Google Scholar
• EDDAHIBI S, RAFFESTIN B, LAUNAY JM, SITBON M, ARNOT S: Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypcoda. Am. Respir. Grit. Care Med. (1998) 157:1111–1119.
   PubMed Web of Science ®Google Scholar
• EDDAHIBI S, HANOUN, LANFUMEY L et al.: Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. Clin. Invest. (2000) 105:1521–1523.
   Google Scholar
• EDDAHIBI A, HUMBERT M, FADEL E et al.: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. .1. Clin. Invest. (2001) 108:1141–1150.
   Google Scholar
• •Considers the connection between the 5-HT-T and PH.
   Google Scholar
• KEEGAN A, MORECROFT I, SMILLIE D, HICKS MN, MACLEAN MR: Contribution of the 5-HT1B receptor to hypwda-induced pulmonary hypertension; converging evidence using 5-HT1g-receptor knockout mice and the 5-HT1mp-receptor antagonist GR127935. Circ. Res. (2001) 89:1231–1239.
   PubMed Web of Science ®Google Scholar
• •Discusses the role of the 5-HTB3 receptor in PH.
   Google Scholar
• LAUNAY J-M, HERVE P, PEOC'H K et al.: Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. (2002) 8:1129–1135.
   Google Scholar
• •Evidence linking the 5-HT2B receptor to PH.
   Google Scholar
• DEUCHAR GA, HICKS MN, COBBE SM, DOCHERTY CC, MACLEAN MR: Pulmonary responses to 5-hydroxytryptamine and endothelin- in a rabbit model of left ventricular dysfunction. Cardiovasc. Res. (1998) 38:500–507.
   PubMed Web of Science ®Google Scholar
• SMULDERS YM: Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc. Res. (2000) 48:23–33.
   PubMed Web of Science ®Google Scholar
• MIYATA M, ITO M, SASAJIMA T, OHIRA H, KASUKAWA R: Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats. Chest (2001) 119:554–561.
   PubMed Web of Science ®Google Scholar
• TERRON JA: Role of 5-HT7 receptors in the long-lasting hypotensive response induced by 5-hydroxytryptamine in the rat. Br. Phannacol (1997) 121:563–571.
   Web of Science ®Google Scholar
• DE VRIES P, DE VISSER PA, HEILIGERS JP, VILLALON CM, SAXENA PR: Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats. Naunyn Schiniedebergs Arch. Pharinacol (1999) 359:331–338.
   PubMed Web of Science ®Google Scholar
• VILLALON CM, CENTURION D, BRAVO B et al: Further pharmacological analysis of the orphan 5-HT receptor mediating feline vasodepressor responses: close resemblance to the 5-HT7 receptor. Naunyn Schiniedebergs Arch. Pharinacol (2000) 361:665–671.
   PubMed Web of Science ®Google Scholar
• VILLAZON M, PADIN JF, CADAVID MIet al.: Functional characterization of serotonin receptors in rat isolated aorta. Biol. Phann. Bull. (2002) 25:584–590.
   Google Scholar
• KEEME MJ, BURGGRAAF J, SCHOEMAKER RC, COHEN AF, BLAUW GJ: No evidence of functional involvement of 5-HT2B receptors in serotonin-induced vasodilatation in the human forearm.' Cardiovasc. Pharinacol (2000) 36:699–703.
   PubMed Web of Science ®Google Scholar
• YILDIZ 0, SMITH JR, PURDY RE: Serotonin and vasoconstrictor synergism. Life Sci. (1998) 62:1723–1732.
   PubMed Web of Science ®Google Scholar
• WATTS SW: 5-Hydroxytryptamine-induced potentiation of endothelin-1- and norepinephrine-induced contraction is mitogen-activated protein kinase pathway dependent. Hypertension (2000) 35:244–248.
   PubMed Web of Science ®Google Scholar
• COHEN ML, SCHENCK KW, HEMRICK-LUECKE SH: 5-Hydroxytrptamine1Areceptor activation enhances norepinephrine release from nerves in the rabbit saphenous vein. Pharinacol Exp. Ther. (1999) 290:1195–1201.
   PubMed Web of Science ®Google Scholar
• WATTS SW: Serotonin-induced contraction in mesenteric resistance arteries: signaling and changes in deoxycorticosterone acetate-salt hypertension. Hypertension (2002) 39:825–829.
   PubMed Web of Science ®Google Scholar
• WATTS SW, FINK GD: 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. Am. Physiol (1999) 276:H944–H952.
   PubMed Web of Science ®Google Scholar
• BANES AKL, WATTS SW: Upregulationof arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension. Hypertension (2002) 39:394–398.
   PubMed Web of Science ®Google Scholar
• DOGGRELL SA, CHEN Y-Y: Responsiveness, affinity constants and receptor reserves for serotonin on aortae of aged normotensive and hypertensive rats. Pharmac. Pharmacol (2001) 53:1403–1408.
   PubMed Web of Science ®Google Scholar
• RUSSELL A, BANES A, BERLIN H, FINK GD, WATTS SW: 5-Hydroxytryptamine2B receptor function is enhance in the N(omega)-nitro-L-arginine hypertensive rats. Pharmacol Exp. Ther: (2002) 303:179–187.
   Google Scholar
• SIKORSKI BW, JAMES GM, GLANCE SD, HOD GSON WC, KING RG: Effect of endothelium on diabetes-induced changes in constrictor responses mediated by 5-hydroxytryptamine in rat aorta. Cardiovasc. Pharmacol (1993) 22:423–430.
   PubMed Web of Science ®Google Scholar
• VAN BUREN T, VLEEMING W, KRUTZEN MM et al.: Vascular responses of isolated mesenteric and basilar arteries from short- and long-term diabetic rats. Naunyn Schmidebergs Arch. Pharmacol (1998) 358:663–670.
   PubMed Web of Science ®Google Scholar
• TURNER NC, WHITE P: Effects of streptozotocin-induced diabetes on vascular reactivity in genetically hyperinsulinaemic obese Zucker rats. Cardiovasc. Pharmacol (1996) 27:884–890.
   PubMed Web of Science ®Google Scholar
• SIKORSKI BW, HOD GSON WC, KING RG: Thromboxane A2 receptor stimulation similarly potentiates pressor responses to 5-hydroxytryptamine in perfused hindquarters of non-diabetic and alloxan diabetic rats. Clin. Exper: Pharmacol Physiol (1991) 18:237–244.
   Google Scholar
• NEMECEK GM, COUGHLIN SR, HANDLEY DA, MOSKOWITZ MA: Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc. Natl. Acad. Sci. USA (1986) 83:674–678.
   PubMed Web of Science ®Google Scholar
• PAKALA R, WILLERSON JT, BENEDICT CR: Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation (1997) 96:2280–2286.
   PubMed Web of Science ®Google Scholar
• •Discusses the mitogenic effect of 5-HT.
   Google Scholar
• PAKALA R, BENEDICT C: Synergy between thrombin and serotonin in inducing vascular smooth muscle cell proliferation. Lab. Clin. Med. (1999) 134:659–667.
   PubMedGoogle Scholar
• WATANABE T, PAKALA R, KATAGIRI T, BENEDICT CR: Serotonin potentiates angiotensin II - induced vascular smooth muscle cell proliferation. Atherosclerosis (2001) 159:269–279.
   PubMed Web of Science ®Google Scholar
• WATANABE T, PAKALA R, KATAGIRI T, BENEDICT CR: Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. Hypertens. (2001) 19:2191–2196.
   Web of Science ®Google Scholar
• SHARMA SK, ZAHRADKA P, CHAPMAN D et al.: Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. Pharmacol Exp. Ther. (1999) 290:1475–1481.
   PubMed Web of Science ®Google Scholar
• KOBA S, PAKALA R, WATANABE T, KATAGIRI T, BENEDICT CR: Vascular smooth muscle proliferation: synergistic interaction between serotonin and low density lipoproteins.' Am. Coll. Cardiol (1999) 34: 1644-1651.
   Google Scholar
• WATANABE T, PAKALA R, KOBA S, KATAGIRI T, BENEDICT CR: Lysophosphatidylcholine and reactive oxygen species mediate the synergistic effect of mildly oxidized LDL with serotonin on vascular smooth muscle cell proliferation. Circulation (2001) 103:1440–1445.
   PubMed Web of Science ®Google Scholar
• KOBA S, PAKALA R, KATAGIRI T, BENEDICT CR: Hyperlipemic-very low density lipoprotein, intermediate density lipoprotein and low density lipoprotein act synergistically with serotonin on vascular smooth muscle cell proliferation. Atherosclerosis (2000) 149:61–67.
   PubMed Web of Science ®Google Scholar
• ITO T, IKEDA U, SHIMPO M, YAMAMOTO K, SHIMADA K: Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation (2000) 102:2522–2527.
   PubMed Web of Science ®Google Scholar
• PAKALA R, WILLERSON JT, BENEDICT CR: Mitogenic effect of serotonin on vascular endothelial cells. Circulation (1994) 90:1919–1926.
   PubMed Web of Science ®Google Scholar
• PAKALA R, BENEDICT CR: Effect of serotonin and thromboxane A2 on endothelial cell proliferation: effect of specific receptor antagonists. Lab. Clin. Med. (1998) 131:527–537.
   PubMed Web of Science ®Google Scholar
• TAMURA K, KANZAKI T, SAITO Y et al.: Serotonin (5-hydroxytrypamine, 5-HT) enhances migration of rat aortic smooth muscle cells through 5-HT2 receptors. Atherosclerosis (1997) 132:139–143.
   PubMed Web of Science ®Google Scholar
• RAMAGE AG: Central cardiovascular regulation and 5-hydroxytryptamine receptors. Brain Res. Bull. (2001) 56:425–439.
   PubMed Web of Science ®Google Scholar
• STEYN DW, ODENDAAL HJ: Randomised controlled trial of ketanserin and aspirin prevention of pre-eclampsia. Lancet (1997) 350:1267–1271.
   PubMed Web of Science ®Google Scholar
• BORGDORFF P, FEKKES D, TANGELDER GH: Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation (2002) 106:2599–2593.
   Google Scholar
• VERSTRAETE M: The PACK trial: morbidity and mortality effects of ketanserin: Prevention of Atherosclerotic Complications. Vasc. Med. (1996) 1:135–140.
   PubMedGoogle Scholar
• DOGGRELL SA: Pharmacology of intermittent claudication. Expert Opin. Phannacother. (2001) 2(11):1725–1736.
   PubMedGoogle Scholar
• KILHARA H, HIROSE K, KOGANEI H et al: AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT 2A receptors and prevents laurate-induced peripheral vascular lesion in rats. Cardiovasc. Pharmacol (2000) 35:523–530.
   PubMed Web of Science ®Google Scholar
• KILHARA H, KOGANEI H, HIROSE K, YAMAMOTO H, YOSHIMOTO R: Antithrombotic activity of AT-1015, a potent 5-HT 2A receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. Ear. Phannacol (2001) 433:157–162.
   PubMed Web of Science ®Google Scholar
• JANIAK P, LAINEE P, GRATALOUP Y et al.: Serotonin receptor blockade improves distal perfusion after lower limb ischemia in the fatty Zucker rat. Cardiovasc. Res. (2002) 56:293–302.
   PubMed Web of Science ®Google Scholar
• BOSTON PC, HODGSON WC: Changes in reactivity toward 5-hydroxytryptamine in the renal vasculature of the diabetic spontaneously hypertensive rat.' Hypertens. (1997) 15:769–774.
   Web of Science ®Google Scholar
• TIAN R-X, KIMURA S, KONDOU N et al.: DOI, a 5-HT2 receptor agonist, induces renal vasodilation via nitric oxide in anesthetized dogs. Ear. Phannacol (2002) 437:79–84.
   PubMed Web of Science ®Google Scholar
• HILL PB, DORA KA, HUGHES AD, GARLAND CJ: The involvement of intracellular Ca2+ in 5-HT_ imp receptor-mediated contraction of the rabbit isolated renal artery. Br. Phannacol (2000) 130:835–842.
   Web of Science ®Google Scholar
• KAKOKI M, HIRATA Y, HAYAKAWA H et al.: Effects of vasodilatory P-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension (1999) 33:467–471.
   PubMed Web of Science ®Google Scholar
• MIRANDA FJ, ALABADI JA, LLORENS S et al: Experimental diabetes induces hyperreactivity of rabbit renal artery to 5-hydroxytryptamine. Ear. I Pharmacol (2002) 439:121–127.
   PubMed Web of Science ®Google Scholar
• KASHO M, SAKA M, SASAHARA T et al.: Serotonin enhances the production of Type IV collagen by human mesangial cells. Kidney Int. (1998) 54:1083–1092.
   PubMed Web of Science ®Google Scholar
• GREWAL JS, MUKHIN YV, GARNOVSKAYA MN, RAYMONE JR, GREENE EL: Serotonin 5-HT2A receptor induced TBF-I31 expression in mesangial cells via ERK: proliferative and fibrotic signals. Am. Physiol (1999) 276:F922–F930.
   PubMed Web of Science ®Google Scholar
• GREENE EL, HOUGHTON 0, COLLINSWORTH G et al: 5-HT2A receptors stimulate mitogen-activated protein kinase via H202 generation in rat renal mesangial cells. Am. Physiol Renal. Physiol (2000) 278:F650–F658.
   PubMed Web of Science ®Google Scholar
• GOPPELT-STRUEBE M, STROEBEL M: Signaling pathways mediating induction of the early response genes prostaglandin G/H synthase-2 and egr-1 by serotonin via 5-HT 2A receptors.Physiol (1998)175:341–347.
   Web of Science ®Google Scholar
• HAFDI Z, COUETTE S, COMOY E et al.: Locally formed 5-hydroxytryptamine stimulates phosphate transport in cultured opossum kidney cells and rat kidney. Biochem. (1996) 320:615–621.
   Google Scholar
• BARRADAS MA, GILL DS, FONSECA VA, MIKHAILIDIS DP, DANDONA R: Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Ear. Clin. Invest. (1988) 18:399–404.
   PubMed Web of Science ®Google Scholar
• MALYSZKO J, URANO T, KNOFLER R et al.: Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb. Res. (1994) 75:569–576.
   PubMed Web of Science ®Google Scholar
• ISHIMURA E, NISHIZAWA Y, EMOTO M et al.: Therapeutic effects of sarpogrelate, and new 5-hydroxytrptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy. Nephron (1997) 76:227–229.
   PubMedGoogle Scholar
• OGAWA S, KAZUHISA T, SUGIMURA K et al.: The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients. Clin. Exp. Pharmacol Physiol (1999) 26:461–464.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, YANO M, MINAMI T et al.: Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduced albuminuria in diabetic patients with early- stage diabetic neprhopathy. Diabetes Res. Clin. Piaci (2002) 58:123–129.
   PubMed Web of Science ®Google Scholar
• BLACKBURN TP, THORNBER CW, PEARCE RJ, COX B: ha vitro studies with ICI 169,369, a chemically novel 5-HT antagonist. Ear. Pharmacol (1988) 150:247–256.
   PubMed Web of Science ®Google Scholar
• ISRAILOVA M, SUZUKI F, TANAKA T et al.: Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes. Pharmacology (2002) 65:69–73.
   PubMed Web of Science ®Google Scholar
• NISHIO H, INOUE A, NAKATA Y: Binding affinity of sarpogrelate, a new anti-platelet agent, and its metabolite for serotonin receptor subtypes. Arch. hat. Pharmacodyn. The]: (1996) 331:189–202.
   PubMedGoogle Scholar
• KIKUMOTO R, HARA H, NINOMIYA K et al.: Synthesis and platelet aggregation inhibitory and antithrombotic properties of [2- [(omega- am onoalkoxy) phenyl] ethyl] benzenes. J. Med. Chem. (1990) 33:1818–1823.
   PubMed Web of Science ®Google Scholar